fashion -WSS

fashion

author：knowledge 2025-10-02 00:42:17 - browse：1

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： UpToDate has a racism problem: Dr. Stanley Goldfarb

leisure time

WSS

Lifetime voting ban for felony convictions struck down in Mississippi

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Teen charged with murder as hate crime in killing of NYC dancer O'Shae Sibley: Sources

What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+

Skip the lead apron during X

leisure time

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Cancer drug shortages should be causing more outrage

Skip the lead apron during X

Sports medicine is finally prioritizing gender equality

Medical schools are missing the mark on artificial intelligence

Apple is now the first public company to be valued at $3 trillion

'Screen and refer' systems are hurting patients

At least 13 dead in Texas as scorching temps continue

Eat, drink, but be wary — 4 foods that interact with medications

How one medical school became remarkably diverse

Beware reading your test results before your doctor does

leisure time

Jailed Russian opposition leader Alexey Navalny gets 19 more years in prison

Dexcom's push to bring CGM to type 2 diabetes patients

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Teen charged with murder as hate crime in killing of NYC dancer O'Shae Sibley: Sources

Teen charged with murder as hate crime in killing of NYC dancer O'Shae Sibley: Sources

Jailed Russian opposition leader Alexey Navalny gets 19 more years in prison

focus

leisure time

Wikipedia

focus